TXMD · TherapeuticsMD, Inc.

TherapeuticsMD reported Q1 2026 revenue of $724 thousand, up 84% from $393 thousand in the prior year quarter. This acceleration stems from stronger licensed product sales by Mayne Pharma, as noted in management discussion. Investors should note this growth provides a foundation for scaling royalty streams, though the business model remains tied to partner performance and future royalty rate adjustments.

Operating income narrowed to a loss of $723 thousand from $871 thousand, reflecting 17% year-over-year improvement. Management attributes this to higher revenue alongside reduced operating expenses, including the absence of prior-year write-off expenses and lower professional fees. Operating margin stood at -99.9%, underscoring high fixed costs relative to revenue scale, but the loss contraction signals cost discipline aiding the path toward breakeven.

Net income achieved profitability at $95 thousand, reversing a $653 thousand loss, with diluted EPS of $0.01 versus -$0.06. This swing reflects combined revenue gains, operating improvements, and elevated other income. Specifically, other income rose to support profitability, driven by increased sublease income and higher ANNOVERA royalties from Mayne's sales, per Item 2 discussion. These non-operating elements bridged the gap to positive bottom-line results, highlighting reliance on royalty and sublease dynamics for near-term earnings.

Cash from operations strengthened, with management noting an increase primarily from royalty receivable collections, though partially offset by accounts payable payments and absent prior patent write-offs. This supports liquidity for ongoing operations, yet the company emphasizes primary cash needs for continued activities. Management continues monitoring unresolved net working capital items with Mayne Pharma, where changes could prove material.